SecFilingDex
424B4CIK 0002002988

Retension Pharmaceuticals, Inc.

Final prospectus (424B4) filed .

Final prospectus filed under Rule 424(b)(4) that includes the pricing and related information omitted from the registration statement at effectiveness — the common final prospectus for IPOs and public offerings.

Filing facts

Accession number
0001213900-26-108587
Filer
Retension Pharmaceuticals, Inc.
CIK
0002002988
Form type
424B4
Form description
Final prospectus
Filed at
October 9, 2026
Last verified
October 10, 2026SecFilingDex pulls from EDGAR with daily cadence

More filings from Retension Pharmaceuticals, Inc.

Provenance

SecFilingDex republishes SEC EDGAR data with provenance. EDGAR is the authoritative source. SecFilingDex is independent and not affiliated with the U.S. Securities and Exchange Commission. Nothing on this page constitutes investment, legal, tax, or other professional advice.